Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2

被引：9

作者：

Jeselsohn, Rinath ^{[1
,2
,3
]}

Schiff, Rachel ^{[4
,5
]}

Grinshpun, Albert ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Breast Oncol Ctr, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Div Mol & Cellular Oncol, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA

[4] Baylor Coll Med, Dept Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA

[5] Baylor Coll Med, Dept Mol & Cellular Biol, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA

来源：

CANCER CELL | 2021年 / 39卷 / 10期

关键词：

D O I：

10.1016/j.ccell.2021.08.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Overcoming resistance to CDK4/6 inhibitors is a major clinical challenge. In this issue of Cancer Cell, Freeman-Cook et al. study mechanisms of resistance to CDK4/6 inhibitors by employing a CRISPRa screen. They identify the cyclin E-CDK2 axis and Myc signaling as key pathways of resistance and develop PF-06873600, a selective CDK2/4/6 inhibitor.

引用

页码：1302 / 1305

页数：5

共 50 条

[31] Targeting CDK4/6 in breast cancer
Shanabag, Anusha
Armand, Jessica
Son, Eugene
Yang, Hee Won
EXPERIMENTAL AND MOLECULAR MEDICINE, 2025, 57 (02): : 312 - 322
[32] Targeting CDK4/6 in patients with cancer
Hamilton, Erika
Infante, Jeffrey R.
CANCER TREATMENT REVIEWS, 2016, 45 : 129 - 138
[33] Targeting CDK4/6 for Anticancer Therapy
Qi, Jiating
Ouyang, Zhuqing
BIOMEDICINES, 2022, 10 (03)
[34] Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity
Henri, P.
Prevel, C.
Pellerano, M.
Lacotte, J.
Stoebner, P. E.
Morris, M. C.
Meunier, L.
BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (03) : 678 - 689
[35] Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (vol 12, 5112, 2021)
Alves, Carla L.
Ehmsen, Sidse
Terp, Mikkel G.
Portman, Neil
Tuttolomondo, Martina
Gammelgaard, Odd L.
Hundebol, Monique F.
Kaminska, Kamila
Johansen, Lene E.
Bak, Martin
Honeth, Gabriella
Bosch, Ana
Lim, Elgene
Ditzel, Henrik J.
NATURE COMMUNICATIONS, 2021, 12 (01)
[36] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
Torres-Guzman, Raquel
Baquero, Carmen
Patricia Ganado, Maria
Marugan, Carlos
Bian, Huimin
Zeng, Yi
Rama, Ramon
Du, Jian
Jose Lallena, Maria
CANCER RESEARCH, 2020, 80 (16)
[37] CDK2 regulation through PI3K and CDK4 is necessary for cell cycle progression of primary rat hepatocytes
Wierod, L.
Rosseland, C. M.
Lindeman, B.
Oksvold, M. P.
Grosvik, H.
Skarpen, E.
Huitfeldt, H. S.
CELL PROLIFERATION, 2007, 40 (04) : 475 - 487
[38] MicroRNA miR-302 Inhibits the Tumorigenecity of Human Pluripotent Stem Cells by Coordinate Suppression of the CDK2 and CDK4/6 Cell Cycle Pathways
Lin, Shi-Lung
Chang, Donald C.
Ying, Shao-Yao
Leu, Davey
Wu, David T. S.
CANCER RESEARCH, 2010, 70 (22) : 9473 - 9482
[39] Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
Pandey, Kamal
Park, Nahee
Park, Kyung-Soon
Hur, Jin
Cho, Yong Bin
Kang, Minsil
An, Hee-Jung
Kim, Sewha
Hwang, Sohyun
Moon, Yong Wha
CANCERS, 2020, 12 (12) : 1 - 17
[40] Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer
Gomes, Ines
Gallego-Paez, Lina M.
Jimenez, Maria
Santamaria, Patricia G.
Mansinho, Andre
Sousa, Rita
Abreu, Catarina
Suarez, Eva Gonzalez
Costa, Luis
Casimiro, Sandra
CELL REPORTS MEDICINE, 2023, 4 (08)

← 1 2 3 4 5 →